ライフサイエンスコーパス: noggin

1 g overactive BMP signaling in the absence of Noggin.

2 netic protein) antagonist, either Chordin or Noggin.

3 can be mimicked by BMP2/4 and suppressed by Noggin.

4 that of the known BMP2-selective antagonist, Noggin.

5 effects were abolished by the BMP antagonist noggin.

6 and the bone morphogenetic protein inhibitor Noggin.

7 morphogenetic protein (BMP) decoy receptor, noggin.

8 ulatory effect is blocked by BMP antagonist, noggin.

9 to maintain expression of the key morphogen noggin.

10 al progenitor cell production in response to Noggin.

11 increased by knockdown of follistatin and/or noggin.

12 avian retrovirus encoding the BMP antagonist Noggin.

13 G mutations are due to haploinsufficiency of NOGGIN.

14 ocytes by BMPs were blocked by the inhibitor noggin.

15 are incorporated into somites and synthesize Noggin.

16 le differentiation by serving as a source of Noggin.

17 y analyzing mice lacking the BMP antagonist, Noggin.

18 tiation was induced, which was reversible by noggin.

19 brogated by a physiological BMP-2 inhibitor, noggin.

20 erve injury in vivo and a negative effect of Noggin.

21 d increasing production of the BMP inhibitor noggin.

22 eta1 (1 ng/ml), as well as the BMP inhibitor noggin (1, 10, and 100 ng/ml).

23 ry development by analyzing null embryos for noggin, a Bmp 2 and 4 antagonist.

24 We also analyzed the role of Noggin, a BMP antagonist, in IVD tissue and examined its

25 Overexpression of noggin, a BMP antagonist, in mouse skin resulted in a ma

26 (KRT14) promoter-mediated overexpression of Noggin, a BMP antagonist, modulates BMP activity.

27 The addition of DKK-1 and Noggin, a BMP inhibitor, to CM diminished PCa CM-induced

28 The addition of Noggin, a BMP-2 antagonist, neutralized the stimulatory

29 Moreover, inhibiting BMP2 signaling by Noggin, a BMP2 antagonist, results in significant inhibi

30 Here we address the functions of Noggin, a dedicated BMP antagonist, in the developing mo

31 Furthermore, exposure of A33 cells to noggin, a naturally occurring BMP-4-binding antagonist,

32 signaling pathways by which IGF-1 suppresses noggin, a potent inhibitor of BMP-7.

33 gnaling is also reduced by administration of Noggin, a soluble BMP antagonist, indicating that the ac

34 The fact that noggin abolishes C2C12 alkaline phosphatase activity sug

35 BMP inhibitors matrix Gla protein (MGP) and Noggin; activin-like kinase receptor (ALK)1, -2, -3 and

36 ulture and show that the effects of BMP4 and NOGGIN activities converge on P63+ epithelial cells loca

37 expense of other precursors, suggesting that Noggin acts on NSCs in vivo.

38 We demonstrate that Noggin acts, in part, by reducing the BMP signal in the

39 injected with adenoviral BDNF and adenoviral Noggin (AdBDNF/AdNoggin) recruited BrdU(+)betaIII-tubuli

40 BMPs and noggin alter cell proliferation in tongue epithelium in

41 er warfarin, BMP-2, nor the BMP-2 antagonist noggin altered runx2 mRNA content in aortas, and noggin

42 miR-200c repressed noggin, an antagonist of Bmp signaling.

43 chymal cells into the collagen gels, whereas noggin, an antagonist of BMPs, or dominant-negative (dn)

44 Moreover, Noggin, an endogenous BMP signaling antagonist, inhibite

45 bitor, LDN-193189, or BMP ligand antagonists noggin and ALK3-Fc.

46 Remarkably, noggin and anti-BMP antibodies also prevented purified F

47 which was blocked by both the BMP inhibitor noggin and anti-BMP-6.

48 ggin can induce Fgf8 expression, we examined noggin and BMP signaling in the Emx2 mutant.

49 xpressed by this embryonic tissue, including Noggin and Chordin, can mimic this inhibitory role.

50 with bicistronic lentiviral vector encoding Noggin and enhanced green fluorescent protein (EGFP) ena

51 BMP signaling and prevents the expression of noggin and follistatin before and after the onset of gas

52 tic proteins, BMP2, 4 and 7, and antagonists noggin and follistatin, in development of papillae from

53 oregulated by several genes including SMAD6, Noggin and Gremlin, and autoregulators are possible targ

54 n the head is induced by the BMP inhibitors, Noggin and Gremlin, and the Wnt inhibitor, Frzb.

55 We also determined that Noggin and Gremlin, but not Chordin, trigger endocytosis

56 elium depends on the local concentrations of noggin and is mediated at least in part via stage-depend

57 helial dysfunction and hypertension and that noggin and its analogs could be used as therapeutic agen

58 gonists was abolished by BMP antagonism with Noggin and mimicked by stimulation with recombinant BMP-

59 action of two inhibitors of SMAD signaling, Noggin and SB431542, is sufficient to induce rapid and c

60 ion has been extended to naturally expressed noggin and sclerostin from the rat osteosarcoma cell lin

61 regulation of SMAD inhibitory factors [i.e., noggin and SMAD6 (inhibitory SMAD)]; and (iii) upregulat

62 ed osteogenesis through a down-regulation in Noggin and suggest a novel approach to clinically accele

63 not inhibited by the BMP-specific antagonist Noggin and, hence, are independent of BMP ligand.

64 retinal cells were grown in the presence of Noggin and/or inductive cues such as Shh and IGF-1.

65 ultures in the presence of the Bmp inhibitor Noggin, and by crossing a Bmp4 mutation into the RBPJ/Ax

66 down-regulation of the potent BMP antagonist Noggin, and examined the effects on the bone forming cap

67 function of three BMP antagonists, chordin, noggin, and follistatin, in Xenopus tropicalis.

68 BMP antagonists follistatin, noggin, and matrix Gla protein were expressed in culture

69 is induced in response to a BMP antagonist, noggin, and that Xfz7 can induce neural crest specific g

70 enhancer is attenuated by the BMP antagonist Noggin, and the enhancer is not activated in Bmp4-null e

71 rker Xbra and the organizer markers chordin, noggin, and Xlim1.

72 +/-) mice and significantly increased in NSE-noggin animals.

73 chordin null slices, but bath application of Noggin, another antagonist of BMP signaling pathway, sig

74 Noggin antagonism of BMP signaling increased total numbe

75 ecombinant BMPs with increased resistance to noggin antagonism.

76 mp4 in the paraxial mesoderm consistent with Noggin antagonizing an auto-inductive feed-forward mecha

77 eins (BMPs), and balanced levels of BMPs and Noggin are required for proper skeletal formation.

78 esity and further indicates the potential of noggin as a therapeutic target to control obesity.

79 bly expresses an inhibitor of BMP signaling, Noggin, as well as a chemical inhibitor of BMP receptors

80 The exogenously added decoy ligand, noggin, attenuated the anabolic effects of BMP-7, and no

81 Together, these studies show that the BMP-NOGGIN axis regulates patterning of the ventral prostate

82 mulation resulted in increased expression of noggin, BAMBI, and FSTL1 in human small airway epithelia

83 ion studies demonstrated increased levels of noggin, BAMBI, and FSTL1 in the lungs of bleomycin-treat

84 hat overexpression of the Shh-dependent gene Noggin, but not Sox2 or Sox18, can partially rescue the

85 Noggin, but not Tbx3, induces Pax6 and coexpression of T

86 Noggin, by suppressing subependymal gliogenesis and incr

87 Unlike Tbx3, the neural inducer Noggin can generate retina both within and outside the e

88 Because noggin can induce Fgf8 expression, we examined noggin an

89 We show here that NOGGIN can neutralize budding inhibition by BMP4 and res

90 ing in the stomachs of mice by expression of noggin causes loss of parietal cells, development of tra

91 on 2 and GATA-Smad enhancers were blunted by noggin coexpression, which indicated dependence on bone

92 We propose that the BMPs and noggin, colocalized within papilla placodes and the fung

93 Exogenously supplied Noggin compensated for the ablated epiblast cells.

94 trates that MyoD expressing cells serve as a Noggin delivery system to regulate the morphogenesis of

95 Furthermore, addition of Noggin did not block Smad1 phosphorylation by PP.

96 in altered runx2 mRNA content in aortas, and noggin did not prevent warfarin-induced calcification.

97 or the first time a novel mechanism by which noggin directly induces adipogenesis of mesenchymal stem

98 the increased BMP signaling observed in the Noggin-/- dorsal neural tube is not sufficient to cause

99 es Sox9 expression, while the BMP antagonist noggin down-regulates Sox9 expression in the gizzard mes

100 Beads soaked in the Bmp antagonist Noggin downregulate Gremlin, while beads soaked in Bmp2

101 Mesenchymal expression of the BMP antagonist NOGGIN during prostate development plays a critical role

102 otein (EGFP) enables direct visualization of Noggin effects in homogenous primary cell populations in

103 In Noggin -/- embryos, the gross anatomy of the inner ear i

104 Reduction of noggin enhanced BMP signaling and in vitro osteoblast bo

105 which, due to the lack of the Bmp antagonist Noggin, exhibit elevated Bmp signaling.

106 Moreover, NSC maintenance requires continual Noggin exposure, which implicates BMPs as crucial regula

107 formation after the adoptive transfer of GFP/Noggin-expressing human endothelial cells in mice.

108 FXR2 deficiency leads to increased Noggin expression and subsequently reduced BMP signaling

109 ing molecules have been used to downregulate noggin expression and thereby stimulate BMP signaling an

110 HUVECs transduced with a control GFP and GFP/Noggin expression cassettes, we showed that constitutive

111 ation in lama5(-/-) mesenchyme and triggered noggin expression in an Shh- and PDGF-dependent manner.

112 trated that in contrast to GFP-only control, Noggin expression in endothelial cells abrogated endothe

113 We find prominent Noggin expression in the palatal epithelium along the an

114 is not regulated by FXR2 in the SVZ, because Noggin expression is restricted to the ependymal cells o

115 In contrast, IGF-1 significantly suppressed noggin expression via the phosphatidylinositol 3-kinase/

116 The local release of Shh suppresses dorsal noggin expression, explaining the absence of DLHPs at hi

117 The transgenic mice were analyzed for noggin expression, tissue morphology, cellular compositi

118 erin and amelogenin expression and increased noggin expression.

119 number of extracellular proteins, including noggin, follistatin and members of the DAN (differential

120 t increases in mRNA expression of gremlin 1, noggin, follistatin, and follistatin-like 1 (Fstl1), and

121 1 activation, and both Zic2 and Myf5 require noggin for their activation.

122 Loss of Noggin function leads to overactive BMP signaling, parti

123 These data indicate that chordin and noggin function to limit BMP signaling in the left LPM,

124 ygosity for functional null mutations in the NOGGIN gene has been shown to be responsible for the dis

125 In early cardiac tissues, the Noggin gene is mainly expressed in the myocardial cells

126 ZFNs directed against the noggin gene produced tadpoles and adult animals carrying

127 eny carrying insertions and deletions in the noggin gene with no indication of off-target effects.

128 Non-somite mesoderm treated with Noggin generates many somites that form simultaneously,

129 induces the expression of its own inhibitor, NOGGIN, generating a reaction-diffusion mechanism that u

130 In postnatal neural progenitors, Noggin governs production of OLs versus interneurons thr

131 iation, and pretreatment with both DKK-1 and Noggin had no greater effect than pretreatment with DKK-

132 -dependent and were significantly reduced by noggin in a dose dependent manner.

133 in endothelial cells (HUVECs) do not express Noggin in culture and used these cells for modeling of a

134 oter, were induced by BMP-2 but repressed by noggin in cushion mesenchymal cell cultures.

135 Our findings demonstrate multiple roles of Noggin in different domains for craniofacial skeletogene

136 Conversely, the induction of Noggin in dorsolateral explants from HGEM-Noggin transge

137 However, the roles of the BMP antagonist Noggin in formation of the craniofacial skeleton remain

138 Overexpression of the BMP antagonist Noggin in hair follicles or deletion of the BMP receptor

139 These data clearly provide a novel role for noggin in inducing adipogenesis and possibly obesity and

140 Transgenic expression of noggin in mice increased H pylori- or H felis-induced in

141 Thus, specific interactions between Bmp4 and Noggin in the early embryo are critical for establishmen

142 al cells, was used to regulate expression of noggin in the gastric epithelium of mice.

143 ng BMP signaling via viral overexpression of noggin in the hippocampus or infusion of noggin into the

144 Expression of noggin in the lenses of transgenic mice resulted in a po

145 her with the evidence that overexpression of Noggin in the palatal epithelium does not cause a cleft

146 ansgenic mice that express the BMP inhibitor noggin in the stomach.

147 In E13 cultures, exogenous BMPs or noggin induce increased numbers of fungiform papillae, i

148 Thus, BDNF and Noggin induced striatal neuronal regeneration, delayed m

149 Evaluation of a possible mechanism for noggin-induced adipogenesis of mesenchymal stem cells id

150 Noggin-induced loss-of-function decreased, while BMP4-in

151 We demonstrate that Noggin-induced OPC production requires Olig1 function.

152 ng exogenous SHH into the mesenchyme of RCAS-Noggin-infected embryos did not restore Bmp2 and Bmp4 to

153 ochord-expressed BMP antagonists Chordin and Noggin inhibit endothelial cell migration in vitro, and

154 Abolishing BMP2/4/7 signaling with noggin inhibited VBCM from upregulating fiber marker exp

155 Here we show that BMP-6 is more resistant to noggin inhibition and more potent in promoting osteoblas

156 ulturing DCDMLs for 6 d with the BMP blocker noggin inhibits the canonical FGF-to-ERK pathway upstrea

157 n and pulldown studies we further document a noggin-insensitive direct peptide-protein association be

158 Similarly, injection of Noggin into the postnatal rat eye failed to induce oligo

159 of noggin in the hippocampus or infusion of noggin into the ventricles exerted antidepressant and an

160 Noggin is a glycosylated-secreted protein known so far f

161 Since Noggin is a single exon gene, this data strongly suggest

162 Noggin is a specific antagonist of bone morphogenetic pr

163 Noggin is an antagonist of bone morphogenetic proteins (

164 Noggin is downregulated in the DRG after nerve injury, a

165 By contrast, the Bmp antagonist noggin is expressed dorsally in neural folds containing

166 Noggin is expressed dorsally in the closing neural folds

167 In vivo, Noggin is expressed in the adult dentate gyrus and limit

168 Noggin is expressed in the ventral diencephalon during R

169 In contrast, Noggin is not regulated by FXR2 in the SVZ, because Nogg

170 Thus, Noggin is required for mammalian neurulation in two cont

171 rs in vitro, and blocking BMP signaling with Noggin is sufficient to foster hippocampal cell self-ren

172 enetic proteins (BMPs) and their antagonist, Noggin, is critical for normal development.

173 The addition of Noggin lateral to the somites compensates for the loss o

174 d to standard tongue cultures; BMPs, but not noggin, lead to a decreased tongue size at this stage.

175 The relevance of elevated noggin levels in obesity was confirmed in a preclinical,

176 the mutation-negative patients excluded the NOGGIN locus, providing genetic evidence of locus hetero

177 Morphologic examination of newborn Noggin-/- male fetuses revealed genitourinary anomalies

178 the dorsal and lateral prostates of newborn Noggin-/- males.

179 ese data indicate that LfcinB-suppression of Noggin may eliminate the negative feedback of BMP7, ther

180 for the 2A-inducing activity of FCS and that Noggin may normally inhibit the formation of 2As in the

181 te defect, we conclude from our results that Noggin mediated modulation of BMP signaling is essential

182 ssion in animal explants and is required for Noggin-mediated neuralization.

183 Wild-type color in K5-Noggin mice is restored by administration of a synthetic

184 resulting inflammation in Hand2(+/-) and NSE-noggin mice was compared with that of wild-type litterma

185 enic mice that have greater than normal (NSE-noggin mice, which overexpress noggin under the control

186 Noggin(-/-) mice exhibited a solitary median maxillary i

187 data suggest that increased Bmp signaling in Noggin(-/-) mice results in downregulation of the hedgeh

188 In Noggin(-/-) mice, the expression domains of Shh, as well

189 Furthermore, Noggin mimics notochord-based inhibition by preventing m

190 ment of hairs within the nipple of the KRT14-Noggin mouse.

191 DG neurogenesis by reducing the stability of Noggin mRNA.

192 The major heart phenotypes of Noggin mutant embryos are thicker myocardium and larger

193 an extensive rescue of the axial skeleton of Noggin mutant embryos.

194 Here we use targeted Noggin mutant mice as a model for gain of BMP signaling

195 g Bmp4 dosage on the skeletal development of Noggin mutant mice.

196 cardium, we show that the cardiac defects of Noggin mutants are rescued by halving the gene dosage of

197 Thus the enlarged outflow tract cushion of Noggin mutants likely arises by increased contributions

198 rast, the appendicular skeletal phenotype of Noggin mutants was unchanged.

199 ive to the position of the inner ears, as in Noggin mutants.

200 the size of the otic capsule is increased in Noggin -/- mutants, which most likely is due to unoppose

201 only one was found to be heterozygous for a NOGGIN mutation (W205X).

202 l body wall, a decrease in the expression of Noggin, MyoD, Myf5, and myosin in the somites and limbs,

203 By contrast, the BMP antagonists noggin (Nog) and chordin (Chrd) are expressed at higher

204 mouse embryos mutant for the BMP antagonists noggin (Nog) and gremlin 1 (Grem1) to characterize the e

205 e bone morphogenetic protein (BMP) inhibitor noggin (Nog) are present in the epiblast before gastrula

206 Mutations of the NOGGIN (NOG) gene in humans are associated with several

207 ic gene ablation approach to assess roles of Noggin (Nog) in two different tissue domains potentially

208 n early tooth development using a transgenic noggin (Nog) overexpression model (K14Cre;pNog).

209 bone morphogenetic protein (BMP) antagonist NOGGIN (NOG).

210 o, using either a BMP receptor antagonist or noggin (Nog).

211 days of differentiation induced by Wnt3a and Noggin (Nog).

212 Noggin null embryos have a variable pituitary phenotype,

213 Noggin null mice die at birth with a severely malformed

214 d dorsally in neural folds containing DLHPs, noggin-null embryos show markedly reduced dorsolateral b

215 t differentiation, whereas pretreatment with Noggin only partially reduced osteoblast differentiation

216 eased BMP activity, either from injection of noggin or a dominant negative BMP receptor, was transpla

217 stable overexpression of the BMP antagonist noggin or a dominant-negative BMP receptor in normal EBs

218 hich was prevented by neutralizing BMP4 with noggin or anti-BMP4.

219 of which were prevented either by coinfusing noggin or by treating the isolated aortas with apocynin.

220 periostin expression was repressed by adding noggin or dnBMPR-1B (ALK6)-virus to the culture.

221 s ectopic HPs identical to those produced by noggin or dominant-negative BMPR1A.

222 ce was critical as exogenous introduction of noggin or sonic hedgehog (Shh) produced downstream from

223 c mice that express either the BMP inhibitor noggin or the beta- galactosidase gene under the control

224 rder can result from mutations in either the NOGGIN or the GDF5 gene.

225 Cotreatment with the BMP antagonist noggin or the NADPH oxidase inhibitor apocynin completel

226 Mice treated with AAV4-BDNF/noggin or with BDNF and noggin proteins actively recruit

227 e Wnt pathway (endostatin), the BMP pathway (Noggin), or the ER pathway (ICI182780) blocked the fluid

228 in mice that overexpress the BMP antagonist, noggin, or BMP4 in the primordial ENS.

229 ice overexpressing either the BMP inhibitor, noggin, or BMP4 under control of the neuron specific eno

230 The developmental defects in the ENS of noggin-overexpressing mice caused a relatively mild dist

231 In contrast, noggin overexpression decreased numbers of neurons deriv

232 Transgenic Noggin overexpression in the SGZ increases multiple prec

233 el-retaining cells exist in the SGZ and that Noggin overexpression increases their numbers.

234 We asked whether BDNF/Noggin overexpression might be used to recruit new stria

235 Addition of NOGGIN partially restores prostatic budding in UGS expla

236 The severe Noggin phenotype correlates with Bmp4-dependent ectopic

237 indicate that antagonism of BMP signaling by Noggin plays a critical role in ensuring proper levels o

238 ence RNA (siRNA) or antagonism of BMP-2 with noggin prevented matrix mineralization in vitro.

239 d with differences in the number of residual Noggin producing, MyoD-positive cells in ocular tissues.

240 rphogenetic protein (BMP) signaling, such as Noggin, promote oligodendrocyte precursor cell (OPC) pro

241 (TG) mice overexpressing the BMP antagonist noggin (promoter, K5) are characterized by a marked incr

242 , we showed that constitutive and orthotopic Noggin protein expression did not influence cell prolife

243 Noggin protein is a potent bone morphogenetic protein (B

244 atment with a small molecule inhibitor, with Noggin protein, or by overexpression of a dominant-negat

245 eated with AAV4-BDNF/noggin or with BDNF and noggin proteins actively recruited subependymal progenit

246 BMPs and noggin proteins become progressively restricted to papil

247 All Noggin-/- pups are born with lumbar spina bifida; depend

248 tes, and the addition of the BMP4 inhibitor, Noggin, reduced precursor cell differentiation.

249 cribe the role of a novel Pitx2:miR-200c/141:noggin regulatory pathway in dental epithelial cell diff

250 nal program involving the Pitx2:miR-200c/141:noggin regulatory pathway that is important in epithelia

251 t the neural and retina-inducing activity of Noggin requires Tbx3.

252 he presence of a lysine at this position and noggin resistance among a panel of osteoinductive BMPs.

253 tified lysine 60 as a key residue conferring noggin resistance within the BMP-6 protein.

254 rtantly, BMP inhibition by recombinant human noggin restored the levels of phospho-Smad1/5/8, Olig2 t

255 somite patterning suggests that the loss of Noggin results in the formation of small mispatterned so

256 through RGMb deletion or BMP inhibition with Noggin, retarded early axonal regeneration after sciatic

257 ing BMP activity by BMP receptor antagonist, noggin, reverse the effects of active astrocytes on OPC

258 he retina and addition of the BMP antagonist Noggin reversed retinal inhibition of oligodendrocyte de

259 Noggin/SB431542-based neural induction should facilitate

260 keys given ICV injections of adenoviral BDNF/noggin showed similar addition of striatal neurons.

261 aturation while maintaining a reciprocal Shh-Noggin signaling loop to drive hair follicle morphogenes

262 nic efficacy of these Sterosomes loaded with noggin siRNA in in vitro two- and three-dimensional sett

263 ular ligand-binding BMP antagonists, such as noggin, SMOC antagonizes BMP activity in the presence of

264 tion of this upregulation by implantation of noggin-soaked beads in head explants also prevented hete

265 d beads and induced in large clusters around noggin-soaked beads.

266 ed dorsolateral bending and local release of noggin stimulates bending.

267 Noggin substantially increases number of papillae in E14

268 ted by prior treatment of the fractions with noggin suggested the activity was induced by BMP rather

269 GF components was inhibited by activation of noggin, suggesting that BMP signalling lies upstream of

270 ized calvarial defects in mice repaired with noggin-suppressed osteoblasts.

271 tionally, misexpression of a BMP antagonist, Noggin, suppresses proepicardium protrusion and contact

272 The effects of noggin suppression on in vivo bone formation were also i

273 The BMP antagonist noggin synergizes with basic fibroblast growth factor (b

274 We produced a K14-Noggin transgenic mouse to modulate bone morphogenic pro

275 of Noggin in dorsolateral explants from HGEM-Noggin transgenic neurulae will block formation of satel

276 z7 can induce neural crest specific genes in noggin-treated ectodermal explants (animal caps).

277 ce, myelination and gliosis were assessed in noggin-treated pups compared with untreated controls.

278 Importantly, the AAV4-BDNF/noggin-treated R6/2 mice showed delayed deterioration of

279 n model in neonatal mice, we have found that noggin treatment inhibits regeneration, thus suggesting

280 Inhibition of BMP signaling by noggin triggered differentiation of hESCs toward neuroec

281 adeno-associated viruses AAV4-BDNF and AAV4-noggin triggered the sustained recruitment of new MSNs i

282 f lobe-specific marker expression in the E14 Noggin-/- UGS rescued by transplantation under the renal

283 e bone morphogenetic protein (BMP) inhibitor Noggin under the control of the neuron-specific enolase

284 n normal (NSE-noggin mice, which overexpress noggin under the control of the neuron-specific enolase

285 bition of BMP signaling by overexpression of Noggin using a Shox2-Cre allele led to a similar DMP hyp

286 Expression of BDNF and noggin via intracerebroventricular (ICV) delivery in an

287 Noggin was found to play a critical role as a negative f

288 ttenuated the anabolic effects of BMP-7, and noggin was substantially increased by BMP-7, suggesting

289 onic hedgehog (Shh) produced downstream from noggin was sufficient to restore hair follicle developme

290 f BMPs in skin tumorigenesis, BMP antagonist noggin was used to generate keratin 14-targeted transgen

291 Recombinant human noggin was used to suppress BMP action; and neurobehavio

292 inding that neither BMP4 nor its antagonist, noggin, was able to alter HJV shedding support the lack

293 MMP-13, ADAMTS-5, and the BMP antagonist noggin were elevated whereas col2a1 and aggrecan were re

294 or treatment with recombinant follistatin or noggin, whereas it was increased by knockdown of follist

295 xpression of the BMP-antagonists Chordin and Noggin, which are required to exclude Vents from the org

296 Among the extracellular BMP antagonists is Noggin, which preferentialy binds to BMP2, BMP4 and BMP7

297 contractility by up-regulating expression of Noggin, which reduced activity of bone morphogenetic pro

298 expression of Sox10 can be maintained using noggin, Wnt3a, Lif and endothelin (NWLE).

299 hat TGF-beta receptor II signaling regulates Noggin, Wnt9a, and growth and differentiation factor-5 j

300 dorsal signaling molecules such as Chordin, Noggin, Xnr6 and Cerberus were not re-expressed in these